The FDA has programs in place to focus on the development and designations for new specialty drugs. The problem is that high prices are being paid for drugs that don’t come with a graded, tested and proven high outcomes guarantee. The Institute for Clinical and Economic Review (ICER) evaluates evidence on the value of medical […]
July 9, 2016 - Curant Health COO, Marc O'Connor, featured in Managed Healthcare Executive - HHS is taking formal steps to address opioid addiction, a widely recognized national public health crisis. These steps include expanding access to buprenorphine—a drug used to treat opioid addiction—a proposal to eliminate any potential financial incentive for doctors to prescribe […]
July 5, 2016 – Atlanta, Georgia – One of the nation’s largest independent 340B specialty pharmacies, Curant Health, announces the launch of four new 340B clinic partnerships beginning July 1, 2016: South Health District - Valdosta, Georgia University of Miami AIDS Clinical Research - Miami, Florida Genesis Health Care, Inc. - Darlington, South Carolina Morehouse […]
When discussing high cost drugs proven to cure a specific illness, such as hepatitis C treatment, it’s important to keep the following in mind: All stakeholders - manufacturers, pharmacy benefit managers, pharmacies, payers and business owners - want a say in determining the cost of certain drugs because they all assume a certain level of […]
July 1, 2016 - Curant Health COO, Marc O'Connor, in Managed Healthcare Executive - Currently FDA provides an array of expedited programs and designations for specialty drugs and biologics intended to facilitate and expedite development and review of new specialty drugs to address unmet medical need in the treatment of a serious or life threatening […]
June 30, 2016 - Atlanta, Georgia - The Atlanta Chapter of the Association for Corporate Growth® (ACG), a global professional organization with the mission of Driving Middle-Market Growth®, ranks Curant Health as #9 of the top 40 fastest-growing upper middle-market companies in Georgia. This year also marks Curant Health as a four time recipient of […]
Value-based contracts between pharmaceutical manufacturers and payers are a fast-growing, new development that is here to stay. These pharma contracts put in place a reward system - higher payment rates - in exchange for demonstrably improved patient outcomes. This type of agreement is intended to reward healthcare value over volume. Some outcomes can be measured […]
As medical cures advance, the umbrella covering chronic conditions does, too. Increasingly, the future of cancer treatment, with increased numbers of immunotherapies and oral oncolytics, will begin to emulate treatments for chronic illnesses. Along with this progress come big questions, like when, if ever will it be safe for a cancer patient to stop treatment? […]
June 2, 2016 - Curant Health COO, Marc O'Connor, in Specialty Pharmacy Times - Signs point to cancer becoming a chronic condition in the near future. According to a study by Wei Zheng, MD, PhD, and others, published in the Journal of the American Medical Association as reported by Reuters in 2015, “For men and […]
June 1, 2016 - Curant Health COO, Marc O'Connor, in Managed Healthcare Executive - Value-based contracts between pharmaceutical manufacturers and payers look like they are here to stay. And they are growing in number. The Wall Street Journal reported last month that payers and PBMs have reached at least a dozen “value-based” or “at-risk” deals […]
